Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 2, 2014, Pages 247-250

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amyloid; Biomarkers; Clinical Dementia Rating Scale; Clinical outcomes; Clinical trials; Composite scales; Diagnostic criteria; Disease modification; Drug development; Food and Drug Administration; Mild cognitive impairment; Neuropsychological tests; Preclinical Alzheimer's disease; Prodromal Alzheimer's disease; Regulatory guidance

Indexed keywords

ALZHEIMER DISEASE; CLINICAL DEMENTIA RATING; DRUG DEVELOPMENT; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; MILD COGNITIVE IMPAIRMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

AMYLOID; BIOMARKERS; CLINICAL DEMENTIA RATING SCALE; CLINICAL OUTCOMES; CLINICAL TRIALS; COMPOSITE SCALES; DIAGNOSTIC CRITERIA; DISEASE MODIFICATION; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PRECLINICAL ALZHEIMER'S DISEASE; PRODROMAL ALZHEIMER'S DISEASE; REGULATORY GUIDANCE;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84897497934     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.002     Document Type: Article

References (13)

1. U.S. Food and Drug Administration. Guidance for industry Alzheimer's disease: developing drugs for the treatment of early stage disease (FDA-2013-D-0077) DRAFT. February 2013 [accessed 2013 June 30]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM338287.pdf.
2. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer Dement 7 2011 270 279
3. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. DeKosky, and P. Barberger-Gateau et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
4. Draft guidance for industry on Alzheimer's disease: developing drugs for the treatment of early stage disease [transcript from FDA Webinar]. March 28, 2013. [accessed 2013 October 20]. Available from: http://www.fda.gov/training/ guidancewebinars/ucm367786.htm.
5. D.A. Bennett, J.A. Schneider, Z. Arvanitakis, J.F. Kelly, N.T. Aggarwal, and R.C. Shah et al. Neuropathology of older persons without cognitive impairment from two community-based studies Neurology 66 2006 1837 1844
6. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, and S. Ferris et al. Vitamin E and donepezil for the treatment of mild cognitive impairment N Engl J Med 352 2005 2379 2388 [see comment]
7. R.C. Petersen, P.S. Aisen, L.A. Beckett, M.C. Donohue, A.C. Gamst, and D.J. Harvey et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology 74 2010 201 209
8. L. Schneider, R. Kennedy, and G. Cutter Amnestic MCI/prodromal Alzheimer's disease with more severe memory deficit is indistinguishable from diagnosed Alzheimer disease: implications for the validity of clinical trials and biomarkers Alzheimers Dement 7 2011 S681 S682
9. J.C. Morris Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia Arch Neurol 2012
10. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack, and C.H. Kawas et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
11. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
12. J.C. Morris The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 1993 2412 2414 [see comment]
13. G.K. Wilcock, S.E. Black, S.B. Hendrix, K.H. Zavitz, E.A. Swabb, and M.A. Laughlin Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7 2008 483 493